$0.78
-0.0109[-1.38%]
At close: Apr 24
$0.78
0[0.00%]
After Hours: 4:02PM EDT
AlloVir
(NASDAQ:ALVR)AlloVir Stock (NASDAQ:ALVR), Analyst Ratings, Price Targets, Predictions
AlloVir Inc has a consensus price target of $35.55, established from looking at the 21 latest analyst ratings. The last 3 analyst ratings were released from B of A Securities, Leerink Partners, and Piper Sandler on December 26, 2023, December 22, 2023, and December 22, 2023. With an average price target of $1.17 between B of A Securities, Leerink Partners, and Piper Sandler, there's an implied 49.57% upside for AlloVir Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
B of A Securities
Leerink Partners
Piper Sandler
JP Morgan
Morgan Stanley
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for AlloVir
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 12/26/2023 | ALVR | Buy Now | AlloVir | $0.78 | 28.21% | B of A Securities | Jason Zemansky | $17 → $1 | Downgrade | Buy → Underperform | Get Alert |
| 12/22/2023 | ALVR | Buy Now | AlloVir | $0.78 | 28.21% | Leerink Partners | Mani Foroohar | → $1 | Downgrade | Outperform → Market Perform | Get Alert |
| 12/22/2023 | ALVR | Buy Now | AlloVir | $0.78 | 92.31% | Piper Sandler | Christopher Raymond | $27 → $1.5 | Downgrade | Overweight → Neutral | Get Alert |
| 12/22/2023 | ALVR | Buy Now | AlloVir | $0.78 | — | JP Morgan | Anupam Rama | — | Downgrade | Overweight → Underweight | Get Alert |
| 08/18/2023 | ALVR | Buy Now | AlloVir | $0.78 | 2079.49% | B of A Securities | Jason Zemansky | → $17 | Initiates | → Buy | Get Alert |
| 08/07/2023 | ALVR | Buy Now | AlloVir | $0.78 | 2464.1% | Morgan Stanley | Michael Ulz | $20 → $20 | Reiterates | Overweight → Overweight | Get Alert |
| 04/26/2023 | ALVR | Buy Now | AlloVir | $0.78 | 2335.9% | SVB Securities | Mani Foroohar | $16 → $19 | Maintains | Outperform | Get Alert |
| 01/27/2023 | ALVR | Buy Now | AlloVir | $0.78 | 2464.1% | Morgan Stanley | Michael Ulz | $27 → $20 | Maintains | Overweight | Get Alert |
| 01/23/2023 | ALVR | Buy Now | AlloVir | $0.78 | 2335.9% | SVB Leerink | Mani Foroohar | $25 → $19 | Maintains | Outperform | Get Alert |
| 11/07/2022 | ALVR | Buy Now | AlloVir | $0.78 | 3105.13% | SVB Leerink | Mani Foroohar | $24 → $25 | Maintains | Outperform | Get Alert |
| 09/09/2022 | ALVR | Buy Now | AlloVir | $0.78 | 3361.54% | Morgan Stanley | Matthew Harrison | $32 → $27 | Maintains | Overweight | Get Alert |
| 07/28/2022 | ALVR | Buy Now | AlloVir | $0.78 | 2848.72% | SVB Leerink | Mani Foroohar | $30 → $23 | Maintains | Outperform | Get Alert |
| 05/19/2022 | ALVR | Buy Now | AlloVir | $0.78 | 4258.97% | Piper Sandler | Christopher Raymond | $55 → $34 | Maintains | Overweight | Get Alert |
| 02/10/2022 | ALVR | Buy Now | AlloVir | $0.78 | 3746.15% | SVB Leerink | Mani Foroohar | $32 → $30 | Maintains | Outperform | Get Alert |
| 01/18/2022 | ALVR | Buy Now | AlloVir | $0.78 | 5669.23% | Morgan Stanley | Matthew Harrison | $48 → $45 | Maintains | Overweight | Get Alert |
| 12/17/2021 | ALVR | Buy Now | AlloVir | $0.78 | 4002.56% | SVB Leerink | Mani Foroohar | — | Maintains | Outperform | Get Alert |
| 11/08/2021 | ALVR | Buy Now | AlloVir | $0.78 | 4643.59% | SVB Leerink | Mani Foroohar | — | Maintains | Outperform | Get Alert |
| 10/12/2021 | ALVR | Buy Now | AlloVir | $0.78 | 6053.85% | Morgan Stanley | Matthew Harrison | — | Maintains | Overweight | Get Alert |
| 09/29/2021 | ALVR | Buy Now | AlloVir | $0.78 | 28746.15% | Morgan Stanley | — | — | Maintains | Overweight | Get Alert |
FAQ
What is the target price for AlloVir (ALVR)?
The latest price target for AlloVir (NASDAQ: ALVR) was reported by B of A Securities on December 26, 2023. The analyst firm set a price target for $1.00 expecting ALVR to rise to within 12 months (a possible 28.21% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for AlloVir (ALVR)?
The latest analyst rating for AlloVir (NASDAQ: ALVR) was provided by B of A Securities, and AlloVir downgraded their underperform rating.
When was the last upgrade for AlloVir (ALVR)?
There is no last upgrade for AlloVir.
When was the last downgrade for AlloVir (ALVR)?
The last downgrade for AlloVir Inc happened on December 26, 2023 when B of A Securities changed their price target from $17 to $1 for AlloVir Inc.
When is the next analyst rating going to be posted or updated for AlloVir (ALVR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AlloVir, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AlloVir was filed on December 26, 2023 so you should expect the next rating to be made available sometime around December 26, 2024.
Is the Analyst Rating AlloVir (ALVR) correct?
While ratings are subjective and will change, the latest AlloVir (ALVR) rating was a downgraded with a price target of $17.00 to $1.00. The current price AlloVir (ALVR) is trading at is $0.78, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.